Researchers from the Pere Virgili Health Research Institute (IISPV) and the Rovira i Virgili University (URV) in Tarragona have developed a software and mobile system based on Artificial Intelligence (AI) for the early detection of diabetic retinopathy. The intention is to commercialize the product for all Catalan primary care centers through the spin-off company RetinaReadRisk.
The system includes two software components: ‘Mira’ automatically reads eye fundus images to identify the presence of diabetic retinopathy, while ‘Retiprogram’ assesses the risk of individuals with type 2 diabetes developing retinopathy.
Currently, the detection of such ocular conditions involves a comprehensive eye examination, mainly conducted in specific primary care centers in Catalonia.
The initiative has formed the spin-off company RetinaReadRisk with support from EIT Health, indicating international potential. The founding partners include IISPV, UP2Smart (URV), TRC Group (Telefónica), and GENESIS Biomed. According to Josep Lluís Falcó, CEO of GENESIS Biomed and acting CEO of RetinaReadRisk, the tool is expected to significantly contribute to national healthcare savings.
In a bid for commercial success, the startup, developed over a decade, will present its project to the Department of Health of the Generalitat, seeking integration into the public primary care network.
Article written by Cristina Aluja